AbbVie reports 4Q15 results

AbbVie Inc. (NYSE:ABBV) reported 4Q15 and 2015 financial results Friday that were in-line with consensus estimates, although its U.S. 4Q sales of HCV regimen Viekira Pak missed expectations.

U.S. Viekira sales were $197 million in 4Q15, missing the $278 million consensus and down sequentially from $242 million in 3Q15. Total 4Q15 Viekira sales were $554 million, just missing the $559 million consensus. For the year, worldwide Viekira sales were $1.6 billion. ...